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Colchicine in patients admitted to hospital with COVID-19 




Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We 
aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with COVID-19.
Methods In this streamlined, randomised, controlled, open-label trial, underway at 177 hospitals in the UK, two 
hospitals in Indonesia, and two hospitals in Nepal, several possible treatments were compared with usual care in 
patients hospitalised with COVID-19. Patients were eligible for inclusion in the study if they were admitted to hospital 
with clinically suspected or laboratory confirmed SARS-CoV-2 infection and had no medical history that might, in the 
opinion of the attending clinician, put the patient at significant risk if they were to participate in the trial. Eligible and 
consenting adults were randomly assigned (1:1) to receive either usual standard of care alone (usual care group) or 
usual standard of care plus colchicine (colchicine group) using web-based simple (unstratified) randomisation with 
allocation concealment. Participants received colchicine 1 mg after randomisation followed by 500 µg 12 h later and 
then 500 µg twice a day by mouth or nasogastric tube for 10 days in total or until discharge. Dose frequency was 
halved for patients receiving a moderate CYP3A4 inhibitor (eg, diltiazem), patients with an estimated glomerular 
filtration rate of less than 30 mL/min per 1·73m², and those with an estimated bodyweight of less than 70 kg. The 
primary outcome was 28-day mortality, secondary endpoints included time to discharge, the proportion of patients 
discharged from hospital within 28 days, and, in patients not on invasive mechanical ventilation at randomisation, a 
composite endpoint of invasive mechanical ventilation or death. All analyses were by intention-to-treat. The trial is 
registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.
Findings Between Nov 27, 2020, and March 4, 2021, 11 340 (58%) of 19 423 patients enrolled into the RECOVERY trial 
were eligible to receive colchicine; 5610 (49%) patients were randomly assigned to the colchicine group and 5730 (51%) 
to the usual care group. Overall, 1173 (21%) patients in the colchicine group and 1190 (21%) patients in the usual care 
group died within 28 days (rate ratio 1·01 [95% CI 0·93 to 1·10]; p=0·77). Consistent results were seen in all 
prespecified subgroups of patients. Median time to discharge alive (10 days [IQR 5 to >28]) was the same in both 
groups, and there was no significant difference in the proportion of patients discharged from hospital alive within 
28 days (3901 [70%] patients in the colchicine group and 4032 [70%] usual care group; rate ratio 0·98 [95% CI 
0·94 to 1·03]; p=0·44). In those not on invasive mechanical ventilation at baseline, there was no significant difference 
in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (1344 [25%] in the 
colchicine group vs 1343 [25%] patients in the usual care group; risk ratio 1·02 [95% CI 0·96 to 1·09]; p=0·47).
Interpretation In adults hospitalised with COVID-19, colchicine was not associated with reductions in 28-day mortality, 
duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.
Funding UK Research and Innovation (Medical Research Council), National Institute of Health Research, and 
Wellcome Trust.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Inflammation is a key feature of severe COVID-19. 
Markedly raised concentrations of inflammatory markers, 
such as C-reactive protein (CRP), ferritin, interleukin-6 
(IL-6), and other cytokines, are observed in severe cases 
and are associated with poor outcomes.1–5 Inflammation 
is particularly prominent in the lung and vascular 
endothelium, and is commonly associated with extensive 
alveolar damage and thrombosis of large and small 
pulmonary vessels.6 Corticosteroids and IL-6 inhibitors 
have both been shown to reduce mortality in patients 
with severe COVID-19; Janus kinase (JAK) inhibitors 
accelerate improvement in clinical status.7–10 Together 
these results show that inflammation is modifiable 
and anti-inflammatory regimens can improve clinical 
outcomes.
Inflammasomes are a key part of the innate immune 
response to SARS-CoV-2 infection. These cytosolic pattern 
recognition receptor systems are activated in response to 
detection of pathogens in the cytosol and stimulate the 
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release of proinflammatory cytokines.11 In COVID-19, 
the degree of inflammasome activation, particularly the 
nucleotide binding domain (NOD)-like pyrin domain 3 
(NLRP3) inflammasome, correlates with disease severity.12 
Colchicine, a readily available, safe, and inexpensive drug, 
has a wide range of anti-inflammatory effects, including 
inhibition of the NLRP3 inflammasome.13 In addition to 
its role in treating acute gout and pericarditis, evidence is 
emerging that colchicine might inhibit endovascular 
inflammation and provide clinical benefits in patients 
with coronary artery disease.14–17 Given the activation of 
NLRP3 in COVID-19 and the presence of vascular 
endothelial inflammation, colchicine has been proposed 
as a treatment for SARS-CoV-2 associated inflammatory 
disease. However, only three small randomised trials have 
assessed the effects of colchicine in hospitalised patients 
with COVID-19, with a total of only seven deaths across 
these studies combined; none of the studies were 
adequately powered to identify any effect of the drug on 
mortality.18–20 Here we report the results of a large 
randomised controlled trial that aimed to evaluate the 
efficacy and safety of colchicine in patients hospitalised 
with COVID-19.
Methods 
Study design and participants 
The RECOVERY trial is an investigator-initiated, 
streamlined, individually randomised, controlled, open-
label, platform trial to evaluate the effects of potential 
treatments in patients hospitalised with COVID-19. 
Details of the trial design and results for other possible 
treatments (dexamethasone,7 hydroxy chloroquine,21 
lopinavir–ritonavir,22 azithromycin,23 tocilizumab,9 and 
convalescent plasma24) have been published previously. 
The trial is underway at 177 hospitals in the UK, two 
hospitals in Indonesia, and two hospitals in Nepal 
(appendix pp 3–25). The trial is supported by the National 
Institute for Health Research Clinical Research Network, 
and is coordinated by the Nuffield Department of 
Population Health (University of Oxford, Oxford, UK), the 
trial sponsor. The trial was done in accordance with 
the principles of the International Conference on 
Harmonisation–Good Clinical Practice guidelines and 
approved by the UK Medicines and Healthcare products 
Regulatory Agency (MHRA) and the Cambridge East 
Research Ethics Committee (20/EE/0101). The protocol, 
statistical analysis plan, and additional information are 
available online.
Patients admitted to hospital were eligible for the 
study if they had clinically suspected or laboratory 
confirmed SARS-CoV-2 infection and no medical 
history that might, in the opinion of the attending 
clinician, put the patient at significant risk if they were 
to participate in the trial. Children and pregnant 
women were not eligible to receive colchicine. Patients 
with severe liver impairment, significant cytopaenia, 
concomitant use of strong CYP3A4 (eg, clarithromycin, 
erythromycin, systemic azole antifungal, and HIV 
protease inhibitor) or P-glycoprotein inhibitors (eg, 
ciclosporin, verapamil, and quinidine), or hyper-
sensitivity to lactose were excluded from the colchicine 
comparison (appendix p 81). Written informed consent 
was obtained from all patients, or a legal representative 
if patients were too unwell or unable to provide consent.
Randomisation and masking
Baseline data were collected using a web-based case 
report form that included demographics, level of 
respiratory support, major comorbidities, suitability of 
the study treatment for a particular patient, and treatment 
Research in context
Evidence before this study
We searched medRxiv, bioRxiv, Medline, Embase, and the WHO 
International Clinical Trials Registry Platform from Sept 1, 2019, 
to April 1, 2021, for clinical trials evaluating the effect of 
colchicine treatment in patients hospitalised with COVID-19, 
using the search terms (“SARS-CoV-2.mp” OR “COVID.mp” OR 
“COVID-19.mp” OR “2019-nCoV.mp” OR “Coronavirus.mp” OR 
“Coronavirinae/”) AND (“colchicine.mp” OR “colchicine/”), 
using validated filters to select for randomised controlled trials. 
No language restrictions were applied.
We identified three relevant randomised trials that compared 
colchicine with usual care or placebo in patients hospitalised 
with COVID-19 (two at low risk of bias and one with some 
concerns because of limited information on randomisation 
process and poor clarity regarding the blinding in the study). 
Each trial suggested a potential favourable effect of colchicine 
on outcome measures of clinical improvement or duration of 
hospitalisation. The three trials combined included a total of 
285 patients and seven deaths; even combined, these trials 
were not adequately powered to detect an effect on mortality.
Added value of this study
The RECOVERY trial is the first large, randomised trial to report 
results of the effect of colchicine in patients hospitalised with 
COVID-19. We found no significant effect of colchicine compared 
with usual care alone on 28-day mortality, the probability of 
discharge alive within 28 days, or the probability of progressing 
to the composite outcome of invasive mechanical ventilation or 
death in patients who were not receiving invasive mechanical 
ventilation at randomisation. We saw no evidence of benefit of 
colchicine in any patient subgroup.
Implications of all the available evidence
There is no good evidence that colchicine treatment is of 
clinical benefit for adults hospitalised with COVID-19 compared 
with current usual care.
For more the protocol, statistical 
analysis plan, and additional 
study resource see www.
recoverytrial.net
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availability at the study site (appendix pp 32–34). Eligible 
and consenting, non-pregnant adult patients were 
randomly assigned (1:1) to receive either usual standard 
of care (usual care group) or usual standard of care plus 
colchicine (colchicine group), or one of the other available 
RECOVERY treatment groups, using web-based simple 
(unstratified) randomisation with allocation concealed 
until after randomisation (appendix pp 30–31). For some 
patients, colchicine was unavailable at the hospital at the 
time of enrolment or was considered by the managing 
physician to be either definitely indicated or definitely 
contraindicated. These patients were excluded from the 
randomised comparison between colchicine and usual 
care. Patients received colchicine 1 mg after randomisation 
followed by 500 µg 12 h later and then 500 µg twice a day 
orally or by nasogastric tube for 10 days in total or until 
discharge, whichever occurred first. Dose frequency was 
halved for patients receiving a moderate CYP3A4 
inhibitor (eg, diltiazem), those who had renal impairment 
(estimated glomerular filtration rate <30 mL/min 
per 1·73m²), and patients with an estimated bodyweight 
of less than 70 kg (appendix p 81).
As a platform trial, and in a factorial design, patients 
could be simultaneously randomly assigned to other 
treatment groups: 1) convalescent plasma versus 
casirivimab and imdevimab versus usual care, 2) aspirin 
versus usual care, and 3) baricitinib versus usual care 
(appendix p 31). Until Jan 24, 2021, the trial also allowed 
a subsequent randomisation for patients with progressive 
COVID-19 (evidence of hypoxia and a hyperinflammatory 
state) to receive usual care plus tocilizumab or usual care 
alone. Participants and local study staff were not masked 
to the allocated treatment. The trial steering committee, 
investigators, and all other individuals involved in the 
trial were masked to outcome data during the trial.
Procedures
A single online follow-up form was completed when 
participants were discharged, had died, or 28 days after 
randomisation, whichever occurred first (appendix 
pp 35–41). Information was recorded on adherence to 
allocated study treatment, receipt of other COVID-19 
treatments, duration of admission, receipt of respiratory 
or renal support, and vital status (including cause of 
death). In addition, in the UK, routine health-care and 
registry data were obtained, including information on 
vital status (with date and cause of death), discharge 
from hospital, receipt of respiratory support, or renal 
replacement therapy.
Outcomes
Outcomes were assessed 28 days after randomisation, with 
additional analyses specified at 6 months. The primary 
outcome was all-cause mortality. Secondary outcomes 
were time to discharge from hospital alive within 28 days 
and, in patients not on invasive mechanical ventilation at 
randomisation, receipt of invasive mechanical ventilation 
(including extracorporal membrane oxygenation) or death. 
Prespecified subsidiary clinical outcomes were use of non-
invasive respiratory support, time to successful cessation 
of invasive mechanical ventilation (defined as cessation of 
invasive mechanical ventilation within, and survival to, 
28 days), use of haemodialysis or haemofiltration, cause-
specific mortality, bleeding events, thrombotic events, and 
major cardiac arrhythmias. Information on suspected 
serious adverse reactions was collected in an expedited 
fashion to comply with regulatory requirements.
Statistical analysis
The primary analysis for all outcomes was assessed 
according to the intention-to-treat principle by comparing 
patients randomly assigned to the colchicine group with 
those who were randomly assigned to the usual care 
group, but for whom colchicine was both available and a 
suitable treatment. For the primary outcome, all-cause 
28-day mortality, the log-rank observed minus expected 
statistic and its variance were used to test both the null 
hypothesis of equal survival curves (ie, the log-rank test) 
and to calculate the one-step estimate of the average 
mortality rate ratio. We used Kaplan-Meier survival 
curves to display cumulative mortality over the 28-day 
period. We used the same method to analyse time to 
hospital discharge and successful cessation of invasive 
Figure 1: Trial profile
Of the 11 340 patients randomly assigned to receive colchicine or usual care, 7091 (63%; 3505 [62%] of the colchicine 
group vs 3586 [63%] of the usual care group) patients were additionally randomised to receive convalescent plasma 
or REGN−COV2 or usual care; 7545 (67%; 3747 [67%] of the colchicine group vs 3798 [66%] of the usual care group) 
patients were additionally randomised to receive aspirin or usual care; and 1635 (14%; 802 [14%] of the colchicine 
group vs 833 [15%] of the usual care group) patients were additionally randomised to receive baricitinib or usual care. 
*Number recruited overall during period that adult participants could be recruited into colchicine comparison. 
†Colchicine unavailable and colchicine unsuitable groups are not mutually exclusive. ‡5122 (93%) of 5510 patients 
with completed follow-up at time of analysis received colchicine. §20 (<1%) of 5605 patients with completed 
follow-up at time of analysis received colchicine. ¶Includes 251 (4%) of 5610 patients in the colchicine group and 
306 (5%) of 5730 patients in the usual care group allocated to receive tocilizumab.






19 423 patients recruited*
11 340 eligible for random assignment to colchicine
5610 included in 28-day intention-to-treat
analysis
645 included in second randomisation¶
24 withdrew consent
5730 allocated placebo§
5730 included in 28-day intention-to-treat
analysis
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mechanical ventilation, with patients who died in 
hospital right-censored on day 29. Median time to 
discharge was derived from Kaplan-Meier estimates. For 
the prespecified composite secondary outcome of 
progression to invasive mechanical ventilation or death 
within 28 days in those not receiving invasive mechanical 
ventilation at randomisation, and the subsidiary clinical 
outcomes of receipt of ventilation and use of 
haemodialysis or haemofiltration, the precise dates were 
not available and so the risk ratio was estimated.
Prespecified analyses were done for the primary 
outcome using the statistical test of interaction (test for 
heterogeneity or trend), in accordance with the 
prespecified analysis plan, defined by characteristics at 
randomisation: age, sex, ethnicity, level of respiratory 
support, days since symptom onset, and use of 
corticosteroids (appendix p 115). An exploratory analysis 
of the primary outcome by CRP concentration at 
randomisation was done using a similar approach.
Estimates of rate ratios and risk ratios are shown with 
95% CIs. All p values are two-sided and are shown 
without adjustment for multiple testing. The full 
database is held by the study team, which collected the 
data from study sites and did the analyses at the Nuffield 
Department of Population Health, University of Oxford 
(Oxford, UK).
As stated in the protocol, appropriate sample sizes 
could not be estimated when the trial was being planned 
at the start of the COVID-19 pandemic (appendix p 55). 
As the trial progressed, the trial steering committee, 
whose members were unaware of the results of the trial 
comparisons, determined that sufficient patients should 
be enrolled to provide at least 90% power at a two-sided 
significance level of 0·01 to detect a clinically relevant 
proportional reduction in 28-day mortality of 12·5% 
between the two groups.
On March 4, 2021, the independent data monitoring 
committee did a routine review of the available safety 
and efficacy data. The independent data monitoring 
committee notified the chief investigators that there was 
no convincing evidence that continued recruitment to the 
colchicine comparison would provide conclusive proof of 
worthwhile mortality benefit either overall or in any 
prespecified subgroup. Consequently, recruitment to the 
Colchicine group 
(n=5610)
Usual care group 
(n=5730)
Age, years 63·3 (13·8) 63·5 (13·7)
Age groups, years
<70 3806 (68%) 3850 (67%)
70 to <80 1139 (20%) 1227 (21%)
≥80 665 (12%) 653 (11%)
Sex
Male 3897 (69%) 4012 (70%)
Female 1713 (31%) 1718 (30%)
Ethnicity
White 4344 (77%) 4383 (76%)
Black, Asian, and 
minority ethnic
758 (14%) 813 (14%)
Unknown 508 (9%) 534 (9%)
Number of days since 
symptom onset
9 (6–12) 9 (6–12)
Number of days since 
admission to hospital
2 (1–3) 2 (1–3)
Respiratory support received
None or simple oxygen 3815 (68%) 3962 (69%)
Non-invasive 
ventilation
1527 (27%) 1507 (26%)
Invasive mechanical 
ventilation




86 (44–145) 87 (46–144)
Creatinine, µmol/L 78 (64–96) 78 (65–96)
Previous diseases
Diabetes 1426 (25%) 1470 (26%)
Heart disease 1189 (21%) 1231 (21%)
Chronic lung disease 1208 (22%) 1206 (21%)
Tuberculosis 16 (<1%) 13 (<1%)
HIV 11 (<1%) 20 (<1%)
Severe liver disease* 0 0
Severe kidney 
impairment†
170 (3%) 166 (3%)
Any of the above 2880 (51%) 2963 (52%)
Use of corticosteroids
Yes 5243 (93%) 5360 (94%)
No 363 (6%) 365 (6%)
Missing 4 (<1%) 5 (<1%)
Use of remdesivir 1235 (22%) 1251 (22%)
SARS-CoV-2 PCR test result 
Positive 5456 (97%) 5553 (97%)
Negative 57 (1%) 58 (1%)
Unknown 97 (2%) 119 (2%)
Data are mean (SD), n (%), or median (IQR). No children or pregnant women were 
randomised. *Defined as requiring ongoing specialist care. †Defined as estimated 
glomerular filtration rate less than 30 mL/min per 1·73 m².
Table 1: Baseline characteristics
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colchicine comparison was closed on March 5, 2021, and 
preliminary results were made available to the public.
Analyses were done using SAS (version 9.4) and 
(R version 3.4). The trial is registered with ISRCTN, 
50189673, and ClinicalTrials.gov, NCT04381936.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding authors had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results 
Between Nov 27, 2020, and March 4, 2021, 11 340 (58%) of 
19 423 patients enrolled into the RECOVERY trial were 
eligible to receive colchicine (ie, colchicine was available 
in the hospital at the time of their admission and the 
attending clinician was of the opinion that the patient had 
no known indication for or contraindication to colchicine; 
figure 1). 5610 (49%) patients were randomly assigned to 
the colchicine group and 5730 (51%) were randomly 
assigned to the usual care group (36 [<1%] patients were 
randomly assigned in Nepal and Indonesia). The mean 
age of study participants was 63·4 years (SD 13·8), and 
the median time since symptom onset was 9 days 
(IQR 6–12; table 1; appendix p 44) in both groups. At 
randomisation, 10 603 (94%) of patients were receiving 
corticosteroids.
The follow-up form was completed for 5510 (98%) 
patients in the colchicine group and 5605 (98%) patients 
in the usual care group. Of the patients with a completed 
follow-up form, 5122 (93%) in the colchicine group 
received at least one dose of colchicine. Of those assigned 
to the colchicine group who received at least one dose, 
3823 (75%) received all (or nearly all, missing at most 
1 day of treatment) of their scheduled doses during their 
hospital stay; 4576 (90%) received at least half of their 
scheduled doses (figure 1; appendix p 45). The median 
duration of treatment with colchicine was 6 days 
(IQR 3–9). Use of other treatments for COVID-19 was 
similar between patients in both groups, with 9675 (87%) 
receiving a corticosteroid, 2542 (23%) receiving 
remdesivir, and 1485 (13%) receiving tocilizumab or 
sarilumab (appendix p 45).
Primary outcome data are known for 11282 (99%) of 
the randomly assigned patients. There was no significant 
difference in the proportion of patients who died within 
28-days between the two groups (1173 [21%] patients in 
the colchicine group vs 1190 [21%] patients in the usual 
care group; rate ratio 1·01 [95% CI 0·93–1·10]; p=0·77; 
figure 2). We observed similar results across all 
prespecified subgroups (figure 3) and in an exploratory 
analysis by baseline CRP concentration (appendix p 49). 
In an exploratory analysis restricted to the 11 009 (97%) 
patients with a positive SARS-CoV-2 test result, the result 
was virtually identical to the overall result (rate ratio 1·02 
[0·94–1·10]; p=0·70).
Figure 3: Effect of allocation to colchicine on 28-day mortality by baseline characteristics
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The median time to discharge from hospital alive was 
10 days (IQR 5 to >28) in both groups, and there was no 
significant difference in the probability of being 
discharged alive within 28 days between the two groups 
(3901 [70%] patients in the colchicine group and 
4032 (70%) usual care group; rate ratio 0·98 [95% CI 
0·94 to 1·03]; p=0·44; table 2). Of the patients not on 
invasive mechanical ventilation at baseline, the number 
of patients progressing to the prespecified composite 
secondary outcome of invasive mechanical ventilation or 
death was similar in both groups (1344 [25%] in the 
colchicine group vs 1343 [25%] patients in the usual care 
group; risk ratio 1·02 [95% CI 0·96 to 1·09]; p=0·47). 
Similar results were seen in all prespecified subgroups of 
patients (appendix pp 50–51).
We found no significant differences in the prespecified 
subsidiary clinical outcomes of cause-specific mortality 
(appendix p 46), use of ventilation, successful cessation of 
invasive mechanical ventilation, or need for haemodialysis 
or haemofiltration (table 2). The incidence of new cardiac 
arrhythmias, bleeding events, and thrombotic events was 
also similar in the two groups (appendix p 47). There were 
two reports of a serious adverse reaction believed related 
to colchicine: one patient had severe acute kidney injury 
and one had rhabdomyolysis.
Discussion 
In this large, randomised trial involving more than 
11 000 patients from three countries and more than 
2000 deaths, use of colchicine was not associated with a 
reduction in mortality, duration of hospitalisation, or the 
risk of being ventilated or dying for those not on 
ventilation at baseline. These results were consistent 
across the prespecified subgroups of age, sex, ethnicity, 
duration of symptoms before randomisation, level of 
respiratory support at randomisation, and use of 
corticosteroids.
The benefit of dexamethasone in patients with COVID-19 
requiring respiratory support shows the importance of 
inflammation in this patient group and colchicine was 
proposed as a treatment for COVID-19 based on its anti-
inflammatory activity.25 However, in this large, well 
powered trial, we found no evidence of a benefit from 
colchicine, which suggests that the anti-inflammatory 
properties of colchicine are either insufficient to produce a 
meaningful reduction in mortality risk or are not affecting 
the relevant inflammatory pathways in moderate-to-severe 
COVID-19. The protocol included a maximum of 10 days 
of treatment with colchicine. It is possible that a longer 
duration of therapy might have provided benefit, but most 
participants had stopped colchicine before 10 days either 
because of death, discharge from hospital, or at the 
discretion of the treating clinician. Although, most patients 
in this study received concomitant corticosteroid therapy, 
we saw no evidence that colchicine was beneficial in those 
patients not receiving a corticosteroid.
Strengths of this trial included that it was randomised, 
had a large sample size, broad eligibility criteria, was 
international, and more than 99% of patients were 
followed up for the primary outcome of all-cause 
mortality. However, there are some limitations. Detailed 
information on laboratory markers of inflammation and 
immune response and information on radiological 
features was not collected; therefore, it is not possible 
to assess if the effect of treatment varied between such 
subgroups of patients. Although this randomised trial is 
open-label, the outcomes are unambiguous and were 
ascertained without bias through linkage to routine 
health records.
Three other randomised controlled trials have assessed 
the efficacy of colchicine for the treatment of patients 
hospitalised with COVID-19.18–20 A two day shorter 
duration of hospitalisation was reported in a trial of 
100 patients with laboratory confirmed SARS-CoV-2 
infection and pulmonary involvement—confirmed by 
CT—who were randomly assigned to receive either 
hydroxychloroquine plus colchicine or hydroxy chloro-
quine plus placebo.18 A second trial reported a reduced 
duration of hospitalisation and oxygen therapy in 
36 patients hospitalised with COVID-19 allocated 
colchicine compared with 36 patients allocated usual care, 
which included hydroxychloroquine, azithromycin, and 
methylprednisolone.19 Finally, the GRECCO-19 trial20 
reported a lower rate of clinical deterioration in 55 patients 
randomly assigned to receive colchicine compared with 
50 patients randomly assigned to receive usual care, which 
Colchicine group 
(n=5610)
Usual care group 
(n=5730)
RR (95% CI) p value
Primary outcome
28-day mortality 1173 (21%) 1190 (21%) 1·01 (0·93–1·10) 0·77
Secondary outcomes
Median time to being discharged 
alive, days
10 (5 to >28) 10 (5 to >28) ·· ··
Discharged from hospital within 
28 days
3901 (70%) 4032 (70%) 0·98 (0·94–1·03) 0·44
Receipt of invasive mechanical 
ventilation or death*
1344/5342 (25%) 1343/5469 (25%) 1·02 (0·96–1·09) 0·47
Invasive mechanical ventilation 600/5342 (11%) 591/5469 (11%) 1·04 (0·93–1·16) 0·48
Death 1053/5342 (20%) 1070/5469 (20%) 1·01 (0·93–1·09) 0·85
Prespecified subsidiary clinical outcomes
Receipt of ventilation† 852/3815 (22%) 941/3962 (24%) 0·94 (0·87–1·02) 0·14
Non-invasive ventilation 818/3815 (21%) 904/3962 (23%) 0·94 (0·86–1·02) 0·14
Invasive mechanical ventilation 259/3815 (7%) 228/3962 (6%) 1·18 (0·99–1·40) 0·06
Successful cessation of invasive 
mechanical ventilation‡
88/268 (33%) 81/261 (31%) 1·01 (0·75–1·37) 0·93
Use of haemodialysis or 
haemofiltration§
212/5570 (4%) 203/5683 (4%) 1·07 (0·88–1·29) 0·51
Data are n (%) or n/N (%). RR=rate ratio for the outcomes of 28-day mortality, hospital discharge, and successful 
cessation of invasive mechanical ventilation, and risk ratio for other outcomes. *Analyses exclude those on invasive 
mechanical ventilation at randomisation. †Analyses exclude those on any form of ventilation at randomisation. 
‡Analyses restricted to those on invasive mechanical ventilation at randomisation. §Analyses exclude those on 
haemodialysis or haemofiltration at randomisation. 
Table 2: Effect of allocation to colchicine on key study outcomes
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did not include corticosteroids.20 The total number of 
patients in all three of these trials combined was 285, with 
seven deaths during the follow-up period, meaning that, 
even combined, these three studies are not able to reliably 
assess the effects of colchicine on mortality. By contrast, 
the RECOVERY trial, with more than 11 000 participants 
and more than 2000 deaths, had excellent power to detect 
modest treatment benefits; none were observed.
The RECOVERY trial only studied patients who had 
been hospitalised with COVID-19; therefore, we are not 
able to provide any evidence on the safety and efficacy 
of colchicine used in other patient groups. In the 
COLCORONA trial26 of 4488 non-hospitalised patients 
with laboratory confirmed or clinically suspected 
COVID-19, fewer patients in the colchicine group died or 
were hospitalised within 30 days of randomisation than in 
the placebo group. However, the trial was stopped before 
the scheduled sample size had been fully enrolled due to 
logistical reasons, and the result was not statistically 
significant (odds ratio 0·79 [95% CI 0·61–1·03]; p=0·081).26 
Thus, the role of colchicine in treatment of COVID-19 in 
patients not requiring hospitalsation remains uncertain. 
Future trials in this setting are ongoing.27
In summary, the results of this large, randomised trial 
do not support the use of colchicine in adults hospitalised 
with COVID-19.
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